



1614.

PATENT  
Atty. Docket No. 1534.004

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed: Assistant Commissioner of Patent and Trademarks, Washington, D.C. 20231 on  
June 8, 2000.

Nancy Dodson  
Nancy Dodson

June 8, 2000  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Group Art Unit: 1614

Verena D. Huebner *et al.*

Examiner: Not yet assigned

Serial No.: 09/369,747

Filed: August 6, 1999

Title: **"Estrogen Receptor Modulators"**#6  
#10  
6-15-00  
RECEIVEDJUN 15 2000  
TECH CENTER 1600/2900**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56, §1.97 AND §1.98**

Assistant Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

Sir:

The citations listed on the enclosed Information Disclosure Form PTO-1449 were cited in an International Search Report, dated May 23, 2000, International application number PCT/US 99/17799, and may be material to the examination of the above-identified patent application. A copy of said International Search Report is enclosed for your use. Therefore, Applicants submit these documents in compliance with the duty of disclosure as defined in 37 CFR §1.56, §1.97, and §1.98. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.



PATENT  
Atty. Docket No. 1534.004


This supplemental information disclosure statement under 37 CFR §1.56, §1.97 and §1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that this citation constitutes prior art under 35 USC §102.

The Applicants believe that payment of fees is not required at this time. Applicant has not received the first office action in this matter. However, if the Applicants are mistaken and payment of fees is due, then the office is hereby authorized to charge any additional fees which may be required by this paper, or to credit any overpayment, to our Deposit Account No. 03-1664.

Respectfully submitted,

Dated: 6/7/00

By:

  
David P. Lentini  
Reg. No. 33,944

CHIRON CORPORATION  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, CA 94608  
(510) 923-2906  
(510) 655-3542 (fax)



GAU 1614-#8  
S.B.

PATENT  
Atty. Docket No. 1534.004 3-17-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Verena D. Huebner et al.

Serial No.: 09/369,747

Group Art Unit: 1614

Filed: August 6, 1999

Examiner: to be assigned

For: ESTROGEN RECEPTOR MODULATORS

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56 AND §1.97(b)(3)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The citation listed on the enclosed Supplemental Information Disclosure Form PTO-1449 may be material to the examination of the above-identified patent application. Therefore, Applicants submit this document in compliance with the duty of disclosure as defined in 37 CFR §1.56 and §1.97(b)(3). The Examiner is requested to make the citation of official record in the present application.

This Supplemental Information Disclosure Statement under 37 CFR §1.56 and §1.97(b)(3) is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that this citation constitutes prior art under 35 USC §102 or §103.

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on this 8 day of March, 2001.  
By [Signature]

RECEIVED  
MAR 15 2001  
FCH CENTER 1600/2900

Since the Supplemental Information Disclosure Statement is submitted before the mailing date of a first Office Action on the merits, Applicants do not believe any fee is due in connection with this submission. However, the Commissioner is hereby authorized to charge any deficiencies in fees in connection with this Supplemental Information Disclosure Statement to Deposit Account No. 03-1664. This, however, is not an authorization for payment of Issue Fee.

Respectfully submitted,

By:



---

David P. Lentini  
Attorney for Applicants  
Reg. No. 33,944

March 8, 2001

CHIRON CORPORATION  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, California 94662-8097  
(510) 923-2706  
(510) 655-3542 (fax)